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9ABSTRACT
Asimple slide testandanalysis of imagewasusedtorevealthe pres-
ence ofan acute-phaseresponse insubjectsofacutemyocardial infarc-
tion.Erythrocytestendtoaggregatewhenaninflammatory processlike athe-
rosclerosisincoronary artery disease. Evaluationoferythrocyte adhesive-
ness/aggregation (EAAT)iscurrently availabletothephysiciansindirectly-
by erythrocytesedimentationrate(ESR).TheESRcorrelatespoorly withe-
rythrocyte aggregation,hencea simple slide test usingcitratedbloodwasu-
sedtoevaluate erythrocyte aggregation in grades by microscopicallyan-
dalso byusingimage analysis.
AIM OF THE STUDY:
         Tostudy erythrocyteaggregation and adhesiveness by asimpleslide-
testinsubjects with acuteST-elevatedmyocardial infarction (STEMI) in
predicting the outcome within 1week.
METHODS AND MATERIALS:
Fifty patientsofacuteSTEMIwhocametotheICCUofGovernment Royapet-
tah Hospitalwere includedinthe study, onsetofchestpain within
6hrs,Subjectswithretrosternalchestpainpersistingformorethan30 min  and
with  ST  segment  elevation 1mm in limb leads and 2mm in chest leads
in  at  least  two   contiguous ECGleadswereincludedinthestu-
dy.CitratedbloodwassubjectedtosimpleslidetestandStainedsmears we-
reexamined under400? andgraded into fourgrades.
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OUTCOMES
To find out whether there is any statistically significance between
the grades of erythrocyte aggregation and prognosis of STEMI patients
within 1 week.
Good Prognosis: Recovery is good
Bad Prognosis: Patient developed reperfusion arrhythmias, LVF,
recurrent Infarction, VT and VF, cardiogenic shock, death from cardiac
and non cardiac causes.
RESULTS:
 ‘P’ value between the GradesofRBCaggregationandthe prognosi-
sof the patients with STEMI was <0.05.
CONCLUSION:
EAATisa simple bedside slide testfor erythrocyte aggrega-
tion,whichindirectly find outthe presenceandproportionof inflamma-
tion.Thistest also hasthe potentialto assesstheprognosisofSTEMI pa-
tients. Itcanalsobeusedas ascreeningtestfor patients with STEMI to find
outhigh-riskindividualssothatnecessary interventions (like PCI)couldbe
adopted.
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INTRODUCTION
The main cause of death in the world are up to twelve millions  death per
each year due to cardiac diseases mainly CAD.“MI(myocardial
infarction)isthe irreversible necrosisof heartmuscle due
toprolongedhypoxia leads to ischemic changes in the cardiac muscle
andoccursfromanimbalancebetweenO2supply
anddemand,frequentlycaused by atheromaruptured to form small plaques
that will leads to thrombus development in a coronary arteries. [1]
Red blood cells are mainly involved in a formation and development of
clot orthrombus or clot.  Red cells have some adhesive molecules such
as proteins. They have more intensity of attachment to the
endothelium of coronary blood vessels. EAAT or red cell aggregation
test include in acute-phaseresponse that leads toalterations inthe
membrane component phospholipid, especially in a subjects with high
lipid profile. [2, 3]
 In normal, red cells act against free radicals i.e. reactive O2 or N2
species. Once free radical production more than antioxidant activity of
red cells. At of this stage the morphology or shape of the red cell is
altered that leads to aggregation or rouleaux formation. Once it is
happened, the red cells gets the property to attachment to the coronary
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vascular endothelium, this finally leads to the vascular endothelial
damage. If damages occur in the vascular endothelium that will leads to
adherence of other factors of atheroma formation.[2,4,5,6]
Picture: 1 shows structural changes in RBC tends to aggregation
Red cells aggregation is independent RF for clot or thrombus
formation leads to blockage in both arterial system and venous systems.
These properties of red cells aggregation, would also be easily
identifiable in the small peripheral capillaries with poor circulation. In
this study shows, that there is relation between the atheroma formation in
the vascular system and red cells aggregation.
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Picture: 2 shows red cells leads to thrombus formation
Erythrocyte or red cells aggregation is find out indirectly through
Erythrocyte Sedimentation Rate (ESR). But this has not adequately
correlates with EA. EA can be observed accurately by INFLAMET
(designed in Israel), LORCA, CFA and MyreneRheometer. [2,8,7] These
are expensive tests, here using a simple slide test done at bed side and
very easy method, low expensive, rapid method for detecting the grades
of red cells aggregation by EAAT (EA and adhesiveness test) and
directly seen andassessing the    grades of EA. This method is
usefulfordetect any inflammation occurs in the vascular system.[9]
This simple test will be donetohelpthephysician to know about the
pathology of ASTEMI (acute ST segment elevation MI) patients with their
prognosis and therebyin giving appropriate therapy.  Inthis physician
subjectively assigning the grades of EA under the microscope (oil
immersion field) from subjectsof ASTEMIandcompared with their
prognosis.
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LITERATURE REVIEW
ANATOMY: BLOOD SUPPLY OF THE HEART
Heart muscle supplied by 2 coronary vessels namely rigt and left
coronary vessel, which are the first branches of aorta. Arteries surround
the heart in the manner of crown (hence the name latin word corona
means=crown).
Picture: 3 Blood supply of the Heart
Right coronary vessel supplies whole of the RV and posterior part
of the LV. Left coronary vessel supplies mainly the anterior and lateral
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parts of the LV. There are many variations in diameter of coronary
vessels.
Picture: 4 LAD and its branches
The left coronary vessel originate from left coronary cusp or sinus
of  the  aortic  valve.  It  divides  in  to  LCx  branch  and  left  anterior
descending branch in the AV sulcus. [10]
The LAD branch runs down in the anterior part of LV and reaches
inferior margin and give anastamostic branches to diagonal branch of
right coronary vessel. Septum and anterior heart are mainly supplied by
this branch.
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Picture: 5 shows LCX and its branches
The left circumflex vessel runs through the AV sulcus turn around
the AV sulcus and give branches for anastamosis with right coronary
vessel.  Most  of  the lateral  wall  and part  of  anterior  wall  are supplied by
this vessel. [10]
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Picture:6 RCA and its branches
21
Picture: 7 shows RCA, LAD, LCx with all branches
22
Anatomical variations:
1. In fifty to sixty percent of persons, the RCA is larger and its called
right dominant and supplies more parts of the heart than left vessel.
2. In fifteen to twenty percent  of  persons,  left  vessel  is  larger and its
called left dominant.
3. In twenty to thirty percent of persons, both arteries supply almost
equal[11]
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PATHOPHYSIOLOGY:
The blood supply to the myocardium is decreased due to blockage
of coronary vessels leads to hypoxia there is O2 supply is diminished to
hear muscle. Cardiac ischemia due to prolonged diminution of O2 leads
to incomplete removal of metabolites. There is an imbalance between O2
supply and O2 demand leads to ischemia.
Stable atherosclerotic plaque leads to ischemia and its produce pain
in the chest.  Any dislodgement from this  plaque or  clot  due to spasm of
coronary vessels leads to ACS. The blood flow is very much decreasedin
this condition. Chance of MI due to non atheromatic cause is very less.
The first step and initiating the atheromatous lesion formation is
endothelial injury.  Lesion initiation occurs when endothelial cells,
activated by RF such as hyperlipoproteinemia, it become more permeable
and express the chemottractant molecules that recruits leucocytes,
lymphocytes and monocytes. There is release of enzymes, cytokines and
growth factors will leads to focal necrosis of vessel wall. The
simultaneous repairing process will occur after necrosis and it is called
fibrosis. The ECF lipids are accumulate in the inner layer of the vessel
wall. [12]
24
Picture: 7 pathogenesis of CAD
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Activation of thrombocytes leads to attached to the sub endothelial
adhesion molecules. It has thrombogenic potential and bind with laminin,
fibronectin, collagen and binding to GP Ib receptor to form of vWF.
Endothelial collagen is a strong stimulator of activation of platelets.
The atheroma plaque contains lipid laden macropages in tunica
adventitia release TF (tissue factor) and covert to prothrombin to
thrombin. These are also a potent stimulant for activation of platelet.
ADP, TXnA2, and serotonin are auto stimulatory agonists of PA.
Activated thrombocytes and GP IIb/IIIa both are cross-linked between
each other by vWf or fibrinogen in the end common pathway of PA.
The extent of O2 deprivation leads to patient gets the clinical
symptoms of ASTEMI. It is depends on plaque stability fixed, fissured
and eroded plaque. MI can be manifested as by chest discomfort,
breathlessness, specific or nonspecific ecg changes, decreased myocardial
contractility, decreasedcardiac output and peripheral blood flow. In case
of stable angina, ischemic pain occurs only when O2 demands beyond the
O2 supply seen in incomplete coronary blockage. It is slowly changes
into over a time. [12]
When it is rupture and form thrombus which contain platelets. The
blood flow to the coronary vessel is decreased and it cause myocardial
ischemia  or  infarction.  The  demand  of  O2  and  supply  of  O2  to
myocardial tissue, this imbalance determines reversible MI without
necrosis (unstable angina) or myocardial ischemia with necrosis.
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Acute ischemic condition may leads to impaired contraction of
myocardium due to reduced cardiac output. In acute MI, the basic
alteration is loss of function of the myocardial tissue.     When O2 supply
is further reduced to the tissues leads to defective contraction.
When size of the infarct is increase may leads to affect large
portion of myocardial segment that case failure of pumping capacity of
heart. This leads to LV EDV and LV ESV increase and decrease CO,
stroke volume, and BP. When LV pressure is raised, that leads to
elevation of left atrial pressure. Chronic elevation leads to pressure
changes in the lung capillaries leads to pulmonary edema and CCF. When
CCF occurs it leads to reduced CO and decrease blood flow to the brain
and kidney.
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ST-ELEVATION MI
The main symptom of ischemic heart disease is pain in the chest,
and the history should ask about character of the pain such as radiating to
shoulder,  arm,  upper  back,  jaw  and  chin  and  ask  about  duration  of  the
pain and quality of the pain. Patients presented with any history of
breathlessness, sweating, vomiting and palpitations are noted.
Picture: 8 closed fist sign is called LEVINE sign
Clinical symptoms of acute MI frequently will be elaborated as
discomfort of the chest rather than pain. Classic symptoms of angina are
tightness in the chest, squeezing, feel heaviness in the chest and
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compressing in nature. Less common symptoms are sharp stabbing or
knife like pain. The classic location is pain in the central area of the chest,
left side chest and radiating to neck, arm and back. [13]
Any strain or stress or cold climate can cause angina pain. Ischemic
pain or anginal pain is lasting less than ten minutes, and sometimes
lasting ten to twenty minutes. Stable one is relived by two to five minutes
of rest and NTG. In AMI is mostly associated with intolerable pain in the
chest associated with discomfort in the chest. This also associated with
sweating, nausea, breathlessness and easy fatigue.
30% of the ASTEMI subjects have atypical symptoms clinically
not  associated  with  specific  symptoms  of  MI.  Some  patients  gets  silent
MI.  Patients  with  atypical  symptoms has    worse  prognosis  than  typical
one. Female patients and aged patients are usually to have atypical pain
or nonspecific pain. and the elderly are more likely to have atypical
presentations.
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RISK FACTORS:
NON MODIFIABLE RF:
? Age
? Sex-male
? Positive family history
? Detection polymorphism in the ACE gene
MODIFIABLE RF
? High levels of serum lipids
? History of Smoking
? DM
? SHT
? Chronic ethanol use
? Sedentary life style
? high fibrinogen, factor 7
? c-RP
? high homocystein level in the blood, gout
? type A personality
? obese individuals
? soft water,OCP
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DIAGNOSIS OF ASTEMI:
PHYSICAL EXAMINATION:
The physical examination is quite nonspecific in ACS diagnosis
and it is not useful in differentiating patients with ACS with non cardiac
cause. Subjects with ASTEMI may appear deceptively well without any
clinical signs of distress or may be uncomfortable, pale, cyanotic, and in
respiratory distress. Most important thing in physical examination is to
identify the consequences of acute ischemia.  The patient may have
normal or bradycardicrythm, tachycardiacrythm, or irregular pulses.
Bradycardia are more common in patients with IWMI.    If heart block
and bradicardiac rhythm are associated with AWMI will be bad
prognostic sign. Sometimes BP may be low (hypotension) or high
(hypertension). In AMI, there is impaired contraction of the myocardium
leads to S1 and S2 are decreased. In fifteen to fifteen percentage of
subjects with STEMI have S3 gallop. In subjects with longstanding SHT
or dysfunction of the myocardium have 4th heart  sound  (S4).  S3  also
present in patients with MI with cardiac failure. Sometimes patient with
ASTEMI will have systolic murmur due to impaired function of the
papillary muscle due to infarction. It leads to acute MR with cardiac
failure and also rupture of LV leads to VSD. Differential diagnosis of
ASTEMI like dissection of the aorta can be differentiated by examining
the unequal pulse and early diastolic murmur due to AR. [12]
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ASTEMI patients developed cardiac failure having signs of HF like
bilateral basal crepitations of the lungs, sometimes presented with s3
gallop along with LV failure. They also have signs of CCF, elevated JVP,
swelling of legs, distension of neck vein and hepato jugular reflex.
ELECTROCARDIOGRAM:
The electrocardiographic method is the most useful method for
diagnosing ASTEMI subjects. It is a non invasive less expensive method.
The twelve leads electrocardiogram can gives information to diagnose the
problems and prognosis.
The myocardial tissue necrosis can cause depolarization changes in
the QRS complex. It is differentiate the MI with ASTEMI from Non ST
segment elevation MI. ST segment elevation more than one millimeter in
2 or more leads is classified as ASTEMI, an indication for thrombolytics
treatment. Non STEMI ACS   may present with ST segment depression or
T  wave  inversion  or  transient  ST  segment  elevation.  The  degree  of  ST
segment depression had a prognostic value. Patient with more than0.2mv
had increased mortality.
ECG will inform us about other parameters like HR, duration of the
QRS complex, conduction abnormalities, and presence or absence of a
old infarction which play an important role in the treatment and prognosis
of the STEMI patients. Following thrombolytic treatment the
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electrocardiogram can inform us about the failure of thrombolytic
treatment help us to select which STEMI patient should receive a rescue
percutaneous intervention.
Picture: 9 Normal ECG
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SPECIFIC ELECTROCARDIOGRAM:
The electrocardiogram gives us, information about the site of
blockage of coronary vessels in patient with ASTEMI.
Electrocardiographic leads are useful in localization of ischemia or site of
infarction. [12]
Picture: 10 Types of ASTEMI
• rS deflection in V1 with Q waves in
V2–V4 or decrease in amplitude of
initial R waves in V1–V4
Anterior
• Q waves in V4–V6, I, and aVLAnteriolateral
• QS deflections in V1, V2, V3, and
possibly V4
Anteroseptal
• Q waves in II, III, and aVFInferior
• Q waves in II, III, aVF, and V5 and V6Inferolateral
• Q waves in I and aVLLateral
• Q waves in II, III, and aVF and ST
elevation in right-side V4
RVMI
• Initial R waves in V1 and V2 >0.04 s
and R/S ratio 1True posterior
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ANTERIOR WALL MI:
ST segment elevation is present in chest leads and  depression  lead
III and avF has reciprocal ST segment depression. If this changes absent
in lead avF indicates blockage of distal LAD vessel.
Anterior-ST segment elevation in chest leads from v2 to v5 is
called as anterior wall MI, if there is ST segment elevation in chest leads
from v1 to v4 is called as ASMI.
Picture: 11 AWMI –tomb stone pattern
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Anterolateral  MI  means  ST segment  elevation  in  chest  leads  from
v3 to v6 and lead I and avL, v5 and v6. ST segment elevation especially
in leads I and aVL and fewer changes in chest leads occur in the blockage
of D1 branch of LAD, while ST segment elevation mainly in chest leads
v1 and v2 with reciprocal depression in limb leads II,III,aVF,V5 and V6
occurs when main S1 of LAD is occluded.
Picture: 12 ASMI
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LATERAL MI OR APICAL MI:
ST  segment  elevation  occurs  in  chest  leads  v5  and  v6  with
reciprocal depression in limb lead III and aVF and occasionally in chest
lead v1.
High lateral MI means ST elevation in lead I and aVL. Patient with
high lateral MI is less common than other STEMI.
Picture: 13 High lateral ASTEMI
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INFERIOR MI/RVMI:
ST  segment  elevation  occurs  in  limb  leads  II,III,  and  aVF  with
reciprocal  ST  segment  depression  present  in  limb  leads  I  and  aVL  and
one or more chest leads like v2-v3. This changes are absent in chest leads
with ST segment elevation in v1,  we should suspect  RVMI. Presence of
additional ST segment elevation in lateral chest leads v5, v6 or in leads I
and aVL represents the blockage of LCX and it is called Inferolateral MI.
Picture: 14 IWMI
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RVMI:
ST elevation in leads II, III and aVF and ST segment depression in
reciprocal leads I, aVL and absence of ST depression in V2, v3. ST
elevation present in right sided lead V4R.
Picture: 15 shows RVMI
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Picture: 16Inferolateral ASTEMI
POSTERIOR MI:
Increase R wave amplitude in V1 and V2, ST segment depression
with upright T waves
Q waves and ST segment elevation in posterior chest leads v7-v9,
Posterior MI is always combined with IWMI.
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Picture: 17 shows posterior ASTEMI
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LVMI WITH PAPILLARY MUSCLES (PM) INVOLVEMENT:
Along  with  ST  segment-T  changes  in  LV  leads,  ST  segment
depression in inferior leads are indicates anterolateral PM infarction,
while ST segment depression in lead I or aVL is seen in posteromedial
PM infarction.
DIAGNOSIS OF CULPRIT VESSEL:
The electrocardiogram gives information about the site of blockage
of coronary vesseles in subjects with MI ischemia. Oc Right coronary
vessel blockage causes inferior STEMI, posterior STEMI, inferoposterior
STEMI, inferolateral STEMI, and RVMI. Blockage of Lcx vessel causes
posterior STEMI and lateral STEMI. Blockage of dominant LCx artery is
cause inferoposterior STEMI or posterolateral STEMI. [12]
Blockage  of  LAD branch  causes  ASMI and  AW MI.  Involvement
proximal LAD branch can cause bundle branch block and LAFB.
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PREDICTING RCA OR LCX BLOCKAGE IN IW:
Picture: 18(a) culprit artery diagnosis in IWMI
ST segment elevation in lead III is more than lead II is represents
RCA blockage and ST segment elevation in lead II is more than III
represents LCX blockage. In inferior infarction, ST segment elevation in
lead III is more than II, and combined with ST segment elevation in v1 is
a powerful predictor of proximal right coronary vessel blockage.
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Picture: 18(b) culprit artery diagnosis in IWMI
Inferior MI with ST segment elevation in lateral chest leads v5 and
v6 or in limb leads I and aVL represents LCX blockage. Inferior MI with
ST segment depression in V1-V3 is more frequently associated with LCx
vessel than right coronary vessel blockage. Inferior MI with reciprocal
changes like ST segment depression in aVL predict LCX blockage, while
reciprocal changes in chest leads fromV4 toV6 predict the multi vessels
disease.
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PREDICTING LAD BLOCKAGE IN ANTERIOR MI:
ST  segment  elevation  in  chest  leads  combined  with  ST  segment
depression more than or equal to 1mm predicts LAD proximal to branch
S1 (serptal) or diagonal branch D1. ST segment elevation in V1 and aVR
associated with complete RBBB and ST segment depression in V5
predicts blockage of LAD proximal to S1. Abnormal Q waves in aVL and
ST  segment  elevation  in  I  and  aVL  predicts  blockage  of  proximal  to
D1.ST segment elevation in chest leads with presence of abnormal Q
waves in from V4 to V6 represents LAD blockage distal  to S1 or D1. ST
segment depression in aVL combined with precardial ST segment
elevation represents LAD blockage distal to D1 branch.
Picture: 19 culprit artery diagnosis in AWMI
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ASTEMI MANAGEMENT:
Categorize the patients with STEMI for giving appropriate treatment
depends upon the infrastructure and facilities of the treatment centre.
Picture: 20 flow chart shows STEMI management algorithm
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Table shows STEMI presented with symptoms are classified
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Timi score used to assess the mortality in STEMI patientsto assess
the risk of mortality . [12]
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ANTIPLATELETS: ASPIRIN
162 to 325 mg of aspirin, it inhibits the platelet aggregation and
block  the  production  of  TxA2  and  it  causes  prevention  of
vasoconstriction. It is contraindicated in active APD, bleeding diathesis
and patient allergy to aspirin.
O2 THERAPHY:
O2 should be given at 2 to 4 L/min by nasal mask to maintain
SaO2 level more than 90%. We noted the signs of hypoxia such as
confusion, altered sensorium, restlessness pallor, and cold skin.  Should
treated with high flow oxygen  can reduce the ischemic pain symptoms.
NTG:
NTG causes vasodilatation mainly veins than arteries and it reduces
the both preload and after load of the heart.  Nitroglycerin is not given in
patients SBP is less than 90 mmhg, heart rate (HR) less than 50 or more
than  100  in  the  absence  of  HF.   NTG  should  not  be  given  along  with
phosphodiesterase inhibitor within 1-2days it aggravates hypotension. It
can be given by oral, nasal, sublingual and IV infusion. [12]
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MORPHINE:
Morphine sulfate is the opioid of choice for chest pain especially in
ASTEMI patients who are not relieved by NTG. It may be given at
starting dose of  a  2-to-4-mg IV and it  can be given repeat  dose in every
fifteen minutes until the patient feels better. It can cause both arterial and
venodilator  and decreases the preload and afterload in addition to
analgesic properties in ASTEMI patients. It can cause depress the
respiratory  system and  also  reduction  of  BP.  We monitored  the  BP,  RR,
and O2 saturation carefully.
COPIDOGREL:
Clopidogrel can be given an initial dose of 300mg or 600 mg then
followed by 75mg every day. It is also given before PCI or stent is placed
and continue this drug as 75mg OD daily for at least 12 months. It
inhibits platelets clumping and can be given to ASTEMI patients with a
patient known allergic to aspirin. It should not be given if bypass surgery
is planned within the next 5 to 7 days. It increases a risk of more bleeding
during operation.
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STATINS:
It has pleomorphic activities. It should be given at loading dose
atorvostatin 80mg followed by 40 mg once daily at night time. It lowers
the cholesterol by inhibition of HMG-CoA reductase. It also reduces the
inflammation and protect the cardiac myocytes.
BETA BLOCKERS:
It reduces the myocardial O2 demand and decrease the ventricular
strain. It also reduces mortality and prevent complications due ASTEMI.
It decreases the workload of the heart in patients with dynamic
obstruction of the LVOT. Initial dose should be given as 2 to 5 mg IV in
every five minutes followed by 25 to 50 mg oral BD per day. [12]
Contraindications:
Systolic blood pressure less than 90 mm Hg
hypotension
Cardiogenic shock
Bradycardiacrythms
Heart block , II  and III degree block
Asthma
PAD
CHF
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GP IIB/IIIA INIBITORS:
Many different GP IIb/IIIa antagonists are available. Abciximab is
a chimeric antibody it binds irreversibly to the GP IIb/IIIa antagonists
Eftifibatide is a synthetic heptapeptide that binds reversibly to the GP
IIb/IIIa receptor. Tirofiban is a synthetic small molecule reversible
binding to the GP IIb/IIIa. It should be given as an IV infusion .Reversal
of platelet inhibition after cessation of infusion is more rapid with the
polypeptide or small molecules.
SPIRANOLACTONE:
Arrange for an ECHO to be done within 24 hrs of admission.
Patients with HF and the LV EF is less than or equal to 40%, consider an
aldosterone antagonist such as spiranolactone 25mg od should be
given.[12]
HEPARIN:
Heparin is a specific antithrombotic agent.Thrombin generation
plays a main role in pathogenesis of coronary vessel thrombosis.
Thrombin converts soluble fibrinogen to insoluble fibrin and activates
coagulation factors V and VIII. It activates factor XIII which stabilizes
colt  formation  by  augmenting  fibrin  cross  linking.  It  also  plays  as  a
platelet antagonist.
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Picture: 21 - Drugs interfere with clot formation
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UFH:
Unfractionated heparin has molecular weights varying between
2000 and 20,000.The different size molecules have different effect on the
clotting system. Heparin complexes with antithrombin III and this
complex inactivate factor thrombin and activated factor X. The heparin
antithrombin III complex is not effective against clot-bound thrombin. It
requires careful monitoring and dose adjustment .
The weight based regimen is given to patients with ASTEMI. The
initial loading dose is 60 to 70Units per kilogram and   maximum dose is
5000units, followed by an infusion of 12 to15units per kilogram per hour
and maximum dose is 1000units per hour for 24 to 48hrs and activated
thromboplastin time should be maintained at 60-70seconds.
LMWH:
The low molecular weight heparin has greater bioavailability and
lower protein binding. It has a longer half life .It achieve a more reliable
anticoagulant effect. They can be given in a fixed dose subcutaneously
once  or  twice  a  day.  In  patients  whom  CABG  is  planned,  it  should  be
with  held  and  shifted  to  UFH  in  the  12  to  24  hours  before  surgery.  If
patients less than 75years, initial dose should be given as 30 mg IV bolus
followed by 1 mg per kg subcutaneous once a day not more than 100mg.
Maintenance dose is 1 mg per kg subcutaneous q12hr. If age of the
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patients more 75 years, initial dose should not be given, maintenance
dose is 0.75mg per kg subcutaneous every 12 hours. It should be given
along with aspirin. In conjunction with fibrinolytic therapy, enoxaparin
should be given before 15 minutes and after 30 minutes of thrombolytic
therapy. LMWH may be given duration of 8 days or until discharge. [12]
DIRECT THROMBIN INHIBITORS:
These agents are bind to the catalystic site of thrombin and bind to
thrombin in clot and resistant to agents which degrade heparin. A peptide
which is derived from medicinal leech called as Hirudin. It consist 65
aminoacid and is one of the most potent natural anticoagulant. Hirudin
increased chance of intracranial bleeding compared to heparin.
Bivalirudin may reduce the short-term risk of postischemic
complications relative to high-dose UFH in patients PCI for unstable or
postinfarction angina, but benefits do appear to persist long term.
Similarly, Inogatran does not appear to offer benefits over UFH for the
treatment of patients with ACS. Thus, at this time, there is no clearly
defined role for direct thrombin inhibitors in the medical management of
ACS patients. [12]
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REPERFUSION THERAPHY:
Fibrinolytics therapy and PCI are used in reperfusion therapy in
patients diagnosed with ASTEMI. The aim of fibrinolytics therapy or PCI
is to restore blood flow to the ischemic myocardiam and prevent further
complications of acute coronary syndrome .
FIBRINOLYTICS THERAPHY:
Fibrinolytics are dissolving existing thrombi by converting
plasminogen to plasmin and degrading fibrin clots. The most commonly
used in thrombolysis are streptokinase, alteplase (recombinant tissue–type
plasminogen activator [rt-PA]; reteplase, and tenecteplase. [12]
Fibrinolytic therapy is most effective when given within 3 hours
after symptoms onset, although benefits have been seen when these drugs
were given up to 12 hours. Ideally it should be initiated within 30 minutes
of ASTEMI.
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CONTRA INDICATIONS FOR THROMBOLYTIC THERAPHY
Absolute Contraindications :
? History  of hemorrhagic stroke at any time
? Ischemic stroke within 3 months
? Intracranial neoplasm
? Active internal bleeding excluding menses
? Aortic dissection
Relative contra indications :
? Blood pressure > 180 / 110 or < 90 / 60
? h/o chronic hypertension
? Bleeding diathesis
? Prolonged CPR / 10 min
? Recent trauma within 2 weeks
? Pregnancy
? Active peptic ulcer disease
? h/o prior streptokinase within 5 days to 2 years
? Major surgery less than 3 weeks
? Recent internal bleeding within 2 to 4 weeks.
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STREPTOKINASE:
This agent is derived from hemolytic streptococci. Antibodies may
produce after administration, so retreatment is usually avoided. It may
allergic to patients can be seen in approximately in 5 % treated for the
first time with a recent streptococcal infection. Allergic reactions respond
to antihistamine.  Less than 0.2 % of patients have a serious anaphylaxis.
While on IV administration of streptokinase approximately 15% of
patients will have hypotension, which usually responds to decreasing the
rate  of   IV  infusion  and  expansion  of  volume.  It  can  produces  a
fibrinolytic state for up to 24 h. Streptokinase is less costly than other
fibrinolytic agents.
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OTHER FIBRINOLYTICS:
ALTEPLASE
• Loading dose is 15 mg bolus followed by 0.75mg/kg
over 30 minutes the maximum dose is 50mg then
0.50mg/kg over 60minutes the maximum dose is
35 mg for total dose of 100mg.
RETEPLASE
• 10 unit bolus dose over 2 min second dose should
be given after 30 minutes at the same dose.
TENECTEPLASE
• Weight adjusted dose should be given as a single
dose over 5seconds.<60kg: dose is 30mg, 60-69kg:
dose is 35mg, 70-79kg:dose is 40mg,80-89mg:dose
is 45mg,>90kg:dose is 50 mg.
ANISTREPLASE
• 30mg single dose should be given over 5min.
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PERCUTANEOUS INTERVENTION:
Urgent percutaneous intervention is done in patients with ASTEMI
when available in a timely manner. The door to balloon time is more than
90 min by an skilled operator. Indications for urgent percutaneous
intervention are patients with shock, arrhythmias with patient requiring
pacing methods or  cardioversion, and elderly patient ( age >75). [12]
PROCEDURE:
Percutaneous intervention is the invasive procedures done by
skilled operator. A catheter is passed through the femoral vessel then into
the blocked coronary vessel in order to open blockages and restoration of
the blood flow to the myocardium. PTCA means (Percutaneous
transluminal coronary angioplasty) is the insertion of a catheter with a
balloon  attached  with  tip  that  is  inflated  to  open  the  coronary  vessel.  A
device known as a coronary stent made by a metal mesh can also be
inserted in to the coronary vessel after angioplasty to keep the vessel
open. Drug-eluting stents are used and they are coated with certain
medications like sirolimus that prevent restenosis of the coronary vessel
by reducing inflammation and thrombin formation. Coronary blockages
can also be romoved  by a procedure known as an atherectomy. Once the
coronary vessel is opened with PTCA and brachytheraphy can be done by
the radiation is delivered to the lesion. It helps to prevent narrowing or
reblockage of vessel.
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COMPLICATIONS:
Complications of percutaneous intervention are include hematoma
from the arterial insertion site, decrease peripheral perfusion, arrhythmias
and coronary spasm leads to MI bleeding in the retroperitoneal area,
arrhythmias, coronary vessel spasm leads to MI, ARF, ischemic CVA and
cardiac arrest. [12]
Sudden detorioration of previously stable patients should always
think the "mechanical" complications of acute MI. As a group, these
complications usually involve the tearing or rupture of affected tissue.
These complications are less common in NSTEMI and USA.
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FREE WALL RUPTURE:
It occurs in 10 % of AMI mortolity, usually 1 to 5 days after
ASTEMI.  The LV free wall rupture usually leads to  tamponade and
death in more than 90% of cases. Patients may feel  sudden onset of
severe tearing chest pain. They will be in shock and tachycardicrythm and
may have onset of altered sensorium and restlessness. Increased JVP,
diminished heart sounds, and pulsusparadoxus may be present.  They are
diagnosed by ECHO.
INTERVENTRICULAR SEPTAL RUPTURE:
Rupture of the IVS is more commonly detected clinically than
rupture of the LV free wall, despite the fact that rupture of the LV free
wall is more often detected in autopsy findings. The size of the defect and
the degree of the shunt left to right can be related with prognosis of the
ASTEMI. Clinically, IVS rupture presented with chest pain,
breathlessness, and sudden hearing of pan systolic murmur. This can be
associated with thrill felt in left lower sterna border. This is diagnosed by
doppler study of echocardiography. An O2 step-up of more than 10 %
from  RA  to  RV  samples  is  diagnostic.  Rupture  of  the  IVS  is  more
common in patients with anterior wall MI and patients with extensive (3-
vessel) disease. [12]
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PAPILLARY MUSCLE RUPTURE:
Papillary muscle rupture occurs in approximately 1 percent of
patients with AMI, is more common with inferior MI, and usually occurs
3 to 5 days after AMI. In contrast to rupture of the IVS, papillary muscle
rupture often occurs with a small to medium sized acute MI. Patients may
have relatively limited CAD. Patients present with acute onset of
breathlessness, increasing degree of CHF, and a new pan systolic murmur
consistent with mitral regurgitation. The posteromedial papillary muscle
is most commonly ruptured, because it gets blood supply from one
coronary vessel, usually the right coronary vessel. Echocardiography can
differentiate rupture of a portion of the papillary muscle from other
causes leads to MR. Immediate surgical intervention is the treatment of
choice for this acute MR.
PERICARDITIS:
In  ASTEMI  10  to  20  %  of  patients  will  get  pericardial
inflammation. It is mainly occurs in transmural infarction. It usually
occurs within two to four days after AMI. It is clinically diagnosed by
hearing pericardial friction rubs. This is mostly seen in RV infarction or
inferior wall MI, because the RV lies immediately beneath the chest wall.
Sometimes,the pain of pericarditis can be confused with that of post
infarction angina. Specific nature of the pain is increased while on deep
inspiration and relieved by sitting and leaning forward.  Pericardial
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effusions are associated with pericarditis, it also occurs in the absence of
pericarditis. The resorption rate of post MI pericardial effusions is very
slow, usually taking many months. Post MI syndrome or “dressler
syndrome” occurs 2 to 10 weeks after ASTEMI and patient presented
with high fever, left chest pain and pleuropericarditis. [12]
RV MI:
Isolated RV infarction is very rare, and it is usually seen as a
complication of an IWMI. The RV most commonly receives its blood
supply from the right coronary vessel. In patients with left dominant
systems,  the blood supply may come from the Lcx.  The anterior  portion
of the RV is supplied by branches of the left anterior diagonal vessel.
Approximately  30%  of  IWMI  involve  the  RV.  The  presence  of  RV
infarction is associated with a significant increase in mortality and
cardiovascular complications. RV infarction can be diagnosed by the
presence of ST-segment elevation in the precordial V4R lead in the setting
of an IWMI. The presence of increased JVP or decreased BP in response
to NTG is also suggestive.
The most serious complication of RV infarction is shock. The
severity of the hemodynamic derangement in the setting of RV infarction
is related to the extent of RV dysfunction, the interaction between the
ventricles (the RV and LV share the IVS), and the interaction between the
pericardium and the RV. RV infarction results  in a reduction in RV end-
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systolic pressure, LV end-diastolic size, cardiac output, and aortic
pressure as the RV becomes more of a passive conduit to blood flow. LV
contraction causes bulging of the IVS into the RV, with resultant ejection
of blood into the pulmonary circulation. As a result, RV infarction with
concurrent LV infarction has a particularly devastating effect on
hemodynamic function. Fluid balance and maintenance of adequate
preload are critical in the treatment of RV infarction.
OTHER COMPLICATIONS:
Other complications of ASTEMI that occur but are not usually seen
in the emergency department include LV thrombus formation, thrombosis
of  venous  and  arterial  system,  PE  postinfarction  angina,  and  infarct
extension. [12]
CARDIAC BIOMARKERS:
Initially, WHO had ascribed equal weight to ECG and cardiac
biomarkers for diagnosis of acute MI. However, increasing precision of
CK-MB using assays and increasing value of cardiac troponin assays has
now established the use of cardiac biomarkers as main marker of
myocardial necrosis. Other biomarkers are SGOT and LDH.
Serum cardiac biomarkers of acute ASTEMI are proteins or macro
molecules released from the cardiac cells (myocytes) undergoing
necrosis. 10–14 Markers vary in terms of their molecular weight, cellular
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location, solubility, plasma concentration, clearance, and ability to be
detected accurately in serum with rapid immunochemical techniques. In
general, serial measurements are more sensitive and accurate than initial
single measurements, and serial sampling every 2 to 3 hours is a validated
practice for the rapid exclusion of AMI in acute chest pain patients.
Cardiac biomarkers can be currently described under the following
head:
? Estabilished cardiac biomarkers
? Emerging biomarkers
? Developing biomarkers
ESTABILISHED BIOMARKERS:
MYOGLOBIN:
Myoglobin leaks from necrotic myocardial tissue far more rapidly
than AST, CK and LDH. Early rise and high sensitivity are two properties
that have led to the adoption of myoglobin as part of
multimarkerstratagies. There is also a greater availability of assays for
myoglobin. However, in view of its very poor specificity, myoglobin
appears to be less acceptable than delayed troponin testing. Rapid release
kinetics also make myoglobin usefull for non invasive monitoring of
reperfusion in patients with ASTEMI.
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TROPONIN I and T:
Troponin is at present the preferred biomarker for diagnosis of
AMI. Since it has a higher sensitivity for detecting myocardial injury than
CK-MB and it also provides useful information about prognosis. Blood
samples for measurement of troponin should be drawn on first assessment
and six to nine hours later. Troponin is started to rise two to four hours of
acute MI and remains elevated up to seven days to fourteen days. Normal
level is less than 0.4ng per ml. Although troponin T and troponin I assays
usually provide equivalent clinical information, standardization is a
problem with troponin I since large number of commercially available
assays are available. Each assay has its specific analytical characteristics
and it  is  important  that  clinicians should be conversant  with the s  of  the
particular assay for correct interpretation. Most of the current assays use a
cut-off in clinical practice in the range of 0.03 t0 0.08.
CREATINE KINASE-MB
Creatine kinase-MB(CK-MB) is a cytosolic carrier protein for high
energy phosphates and for a long time, it has been the gold standard for
AMI  diagnosis.  Its  elevation  occurs  four  to  eight  hours,  after  MI  and
peaking occurs at eighteen to twenty four hours. The sensitivity of CK-
MB  for  ASTEMI  is  only  50%  when  measured  early  at  the  time  of
presentation. Its sensitivity and specificity can be increased by serial
testing. Serial testing of CK-MB also enables the physician to detect early
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recurrent infarction. Myocardial damage is likely if the False positive
results can be seen in  muscloskeletal injury, post operative conditions,
RF and peripartam period.
Electrophoretic methods were used to detect isoenzymes originally;
Peak level of markers of necrosis and area under time-release curve of
CK-MB from repetitive serial sampling has been used to estimate infarct
size. After the introduction of cardiac troponin assays in clinical
practice,CK-MB has had a progressive diminution in its role in diagnosis
and prognostication of ACS
EMERGING BIOMARKERS:
? BNP and N-terminal pro BNP
? C-reactive protein
DEVELOPING BIOMARKERS:
? Low sensitivity in the first 4-6 hours after onset of chest pain
? Poor markers of ischemia in absence of myocardial necrosis
? Affected by inflammation or injury to other body systems
1. Myeloperoxidase
2. Soluble CD40 ligand
3. Matrix metalloproteinase-9
4. Fatty acid binding proteins
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5. Ischemia modified albumin
6. Free fatty acid unbound to albumin
7. Placental growth factor
8. PAPA-pregnancy-associated plasma protein A
ECHO
Echocardiography is the most useful and easily available modality
to diagnose ASTEMI. MI results in regional LV (LV) wall motion
abnormality (RWMA) and it present before the symptoms and
electrocardiogram abnormalities in onset. If RWMA is not present during
an episode of chest pain, diagnosis of ASTEMI is unlikely and hence it is
recommended as a diagnostic modality in patients with non
diagnosticeletrocardiogram, especially during pain or shortly after it
ceases. Another common problem is distinguishing RWMA due ischemic
changes from old infarction. Echocardiography also excludes other
causes of chest pain like cardiac tamponade, aortic dissection and PE.
Newer advancements like strain imaging by tissue Doppler technique
hold the potential to detect wall motion abnormalities earlier than
currently used 2D imaging. Assessment of systolic-diastolic LV function
by echocardiography is a strong-determinant of prognosis. [12]
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ERYTHROCYTE SEDIMENTATION RATE:
The erythrocyte sedimentationrate is done by Westergren method
or Wintrobes method. Itisthe commonest test and it is used for measuring
the inflammation rate atwhichErythrocytesedimentation rate done ina
onehour.
EdmundBiernacki invented this test in 1897 and this test called
asbiernacki reaction. The SwedishpathologistsRobertSannoFahraeus
invented this test in 1918 along
withAlfVilhelmAlbertssonWestergren,declaredt h i s m e t h o d
andarereferredasWestergrenmethod which contains sodium citrate-
coagulated specimens. [14]
Whenaninflammation occurs, that leads to increase fibrinogen level in the
serum that causes RBCs to stick to each other.
Theerythrocytesformstackscalledrouleaux formation, whichsettle faster.
[2]
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NORMAL VALUE: ESR
EA AND ADHESIVENESSTEST (EAAT):
EA/ adhesiveness test (EAAT) is asimplebedsideslide test.Itisa very
feasible,cost effective,fastmethodofdirectly visualizingtheEAstatus.Itisa
usefulbiomarker todetectinternalinflammationin individuals with
atherothrombotic risk factors. [9]
1.   Thetest has the potential toassess the risk ofacute MI
2.   It can beused to assess the prognosis in patient with
ASTEMI.
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METHODOLOGY
MATERIALS AND METHODS:
Study design:   Cohort study design
Place of study: Government Royapettah Hospital,
Collaborating Department:
Department of Cardiology, Government RoyapettahHospital,
KilpaukMedical College.
Period of study: May 2014 to Sep 2014
Sample size: 50
Study population (subjects): Patients admitted in ICCU with ASTEMI
at GRH during study period.
Inclusion criteria:
1. Patients admitted in ICCU with acute ASTEMI
2. Left side chest pain more than thirty minutes, within  six hours
ofonset
3. ST segment elevation more than one millimeter in 2 leads in ECG
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Exclusion criteria:   1. Recent MI,
                                2. Sepsis,
                                3. Infections-any bacterial infection
                                4. Neoplasms
                                5. Liver failure,ESRD
                                6. DVT,
                                7. Patient on antiplatelet drugs statins
ASTEMI patientsofallagegroupssattisfy
theinclusioncriteriaandadmitted tothe ICCUof Government Royapettah
Hospital, Kilpauk medical college wereincludedinthe
study.Informedconsentwastakenfromthe patients.Past history of the
patient wasaskedandroutine examination like both general and systemic
examinationwasdone.Completehistory was asked includingRFofthe
coronary vessel diseasewere recorded.Blood
wasdrawnedfromantecubitalvein at the time of admission. The
ASTEMIsubjectsweretreatedbythe
standardtreatmentguidelinesofourhospital.Thebloodsampleswere a n d
d r a w n e d  f r o m  t h e  s u b j e c t s  a n d  immediately
sendtothelaboratoryandESR (erythrocyte sedimentation rate)by
Westergren'smethodandslidetest(EAAT)were performedalongwith
75
otherinvestigations.
1. Fifty subjects of acute ASTEMI admitted to the Department of
Cardiology, Government Royapettahhospital,onset within six
hours,  chest  pain  duration  is  more  than  30  min,  and  two  or  more
contiguous leads with ST segment elevation .
2. Informed consent was taken from the subjects patients with
ASTEMI
3. History was asked from the patients, and routine general
examination and syASTEMIc examination were done. Risk factors
of the CAD were also recorded.
4. Anticoagulatedbloodwasinstilledover the
simpleslideandbloodsmears were stained by leishman stain
andobserved under400? oil immersion field andgraded into four
SLIDE PREPARATION:
           Onedropof citrated anticoagulant mixed with threedropsofblood
and poured over the glass slide.Thiscitrated
anticoagulantbloodwaspouredona slide and positioned the slide at 45
degree. Wait for 10 seconds for blood ran from above downwards and
make a thin smear. The lowest part of the slide was wiped by absorbent
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tissue paper. The slides were kept at room temperature and dried by room
temperature itself.
Thesize of blood drop andthe angle of slides were constant in all
subjects with ASTEMI. Staining was done by 5 to 6 drops of Leishman
stain and wait for two minutes. Distilled water  gently instilled over the
slide double the amount of leishman stain and wait for eight minutes.
Finally, washed under the tap water and dried in room temperature. Oil
immersion field was used for the assess the grades of EA
ANALYSIS OF THE SLIDES
The slides were observed under oil immersion fields in microscope
with fourty× (four hundred×)magnification. The slides were fully
examined and assigned grades of red cell aggregation in to mild
(A),moderate(B),Severe (C) and very severe (D) by the investigator.
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CRITERIA FOR GRADING RED AGGREGATION
GRADE
A:RBCsarediscretewithuniformdistributionthroughoutwithno clear areas
in between. Picture
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GradeB:RBCsareaggregatedinsomeareasoftheslidewith areas of
small clear spaces. picture 11
79
GradeC:Variablesizesoferythrocytes aggregatesinalltheareas
ofslidewithsmall clear spaces. Picture
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GradeD:LargethickRBCaggregateswithrounded/clearbordersandlar
ge clearspaces.Picture
The grades of red cell aggregation were observed by standard criteria.
The grades of EA are compared with prognosis of the ASTEMI patients with
one week follow up.
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PROGNOSIS:
Good prognosiswasdocumented in patients with complete recovery.
Bad prognosiswas documented in patients
? Recurrent chestpain orAngina
? Re- infarction
? LV failure
? Cardiogenicshock
? Cardiac arrhythmias,VT,VF,AF
? Mortality from  cardiac causes
? Mortality from non cardiac causes
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OBSERVATION AND RESULTS
Out of 50 patients males were 38 females were 12. In out of 100
percentage males were 76% and females were 24%.
Freq % Valid % Cumulative %
Valid Male 38 76.0 76.0 76.0
Female 12 24.0 24.0 100.0
Total 50 100.0 100.0
Table: 1 Sex difference of the patients
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Picture: 22 -  sex ratio of the ASTEMI patients
Table: 2 Age and sex distribution of ASTEMI patients
Sex Age in yrs
Males 28-77yrs
Females 44- 75yrs
Overall 28-77yrs
Frequency % Valid % Cumulative %
Valid 21-30 yrs 2 4.0 4.0 4.0
31-40 yrs 5 10.0 10.0 14.0
41-50 yrs 15 30.0 30.0 44.0
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51-60 yrs 16 32.0 32.0 76.0
61-70 yrs 8 16.0 16.0 92.0
71-80 4 8.0 8.0 100.0
Total 50 100.0 100.0
Table: 3 age group with frequency
Picture:  23 -  Age distribution of ASTEMI patients
Age group more commonly came with acute MI are 51-60 years,
next age group are 41-50years then 61-70 years.
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Freq % Valid % Cumulative %
Valid A 5 10.0 10.0 10.0
B 19 38.0 38.0 48.0
C 21 42.0 42.0 90.0
D 5 10.0 10.0 100.0
Total 50 100.0 100.0
Table: 4 Percentage of EA in ASTEMI patients
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Picture: 24 -   % of EA in ASTEMI
Out of fifty patients mild aggregation Grade A are observed in
5(10%) patients, Grade B EA observed in 19(38%) patients. Grade C
aggregation observed in 21(42%) patients. Grade D aggregation observed
in 5(10%) patients.
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EA grades with prognosis of the patient
Frequency % Valid % Cumulative %
Valid Good 37 74.0 74.0 74.0
Bad
13 26.0 26.0 100.0
Total
50 100.0 100.0
Table: 5 Good and Bad Px in total number of cases
Out of fifty patients 12 patients were female and 7(58.3%) patients
had good prognosis and 5(41.7%)  patients had bad prognosis.38(78.9%)
patients were male among this 8(21.1%) patients had bad prognosis.
Out  of  fifty  patients  with  ASTEMI  5  showed  Grade  A  RBCs
aggregation, all of them had Good prognosis (100%).
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Picture: 25 -  Good and Bad Px in total number of patients
Out of fifty patients 13 patients ASTEMI had Bad prognosis within
one week period of followup.37 patients had Good prognosis.
In  patients  Grade  B  RBCs  aggregation  was  observed,  out  of  this
17(89.5%) had good prognosis and 2(10.5%) patients had bad prognosis.
Grade C RBCs aggregation observed in 21 patients, out of this 14 patients
(66.7%) had good prognosis and 7patients (33.3%) had bad prognosis.
Grade D RBCs aggregation observed in 5 patients, out of this 4(80%) had
good prognosis and 1(20%) had good prognosis.
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Prognosis within 1
week period Total
Good Bad
EA grade Mild Count 5 0 5
% within EA grade 100.0% .0% 100.0%
% within Prognosis within
1 week period 13.5% .0% 10.0%
Moderate Count 17 2 19
% within EA grade 89.5% 10.5% 100.0%
% within Prognosis within
1 week period 45.9% 15.4% 38.0%
Severe Count 14 7 21
% within EA grade 66.7% 33.3% 100.0%
% within Prognosis within
1 week period 37.8% 53.8% 42.0%
very Severe Count 1 4 5
% within EA grade 20.0% 80.0% 100.0%
% within Prognosis within
1 week period 2.7% 30.8% 10.0%
Total Count 37 13 50
% within EA grade 74.0% 26.0% 100.0%
% within Prognosis within
1 week period 100.0% 100.0% 100.0%
Table: 6 Grades of EA Vs prognosis
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Picture: 26 - EA grades Vs prognosis with in 1 week
ASTEMI  patients  with  Grades  C  and  D  were  significantly
associated with bad prognosis, similarly Grades A and B were
significantly associated with good prognosis. It was done by Chi-square
Test and the P value is observed P=0.006.This P value is <0.05, hence it is
statistically significant.
Value df Significance p
Pearson Chi-Square 12.286(a) 3 .006
Likelihood Ratio 12.781 3 .005
Linear-by-Linear Association 10.648 1 .001
N of Valid Cases 50
Table:7 Chi-square test
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Sex ratio Vs Prognosis:
Prognosis within 1
week period Total
Good Bad
Sex Male Count 30 8 38
% within Sex 78.9% 21.1% 100.0%
% within Prognosis
within 1 week
period
81.1% 61.5% 76.0%
Female Count 7 5 12
% within Sex 58.3% 41.7% 100.0%
% within Prognosis
within 1 week
period
18.9% 38.5% 24.0%
Total Count 37 13 50
% within Sex 74.0% 26.0% 100.0%
% within Prognosis
within 1 week
period
100.% 100.0% 100.0%
Table:8 Prognosis in males Vs Females
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Picture: 27 - Sex ratio Vs Px
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OTHER VARIABLES COMPARED WITH GRADES OF EA
ANOVA
Sum of
Squares df Mean Square F Sig.
SGOT Between Groups 1050.657 3 350.219 1.466 .236
Within Groups 10988.623 46 238.883
Total 12039.280 49
Cardiac
Enzymes -
CPK – MB
Between Groups
311.461 3 103.820 .980 .410
Within Groups 4872.859 46 105.932
Total 5184.320 49
Cardiac
Enzymes -
TROP  - T
Between Groups
1.949 3 .650 1.627 .196
Within Groups 18.371 46 .399
Total 20.320 49
TG Between Groups 644.964 3 214.988 1.067 .373
Within Groups 9272.256 46 201.571
Total 9917.220 49
LDL Between Groups 689.788 3 229.929 1.957 .134
Within Groups 5403.332 46 117.464
Total 6093.120 49
HDL Between Groups 133.507 3 44.502 1.450 .241
Within Groups 1412.173 46 30.699
Total 1545.680 49
Total
Cholesterol
Between Groups 970.333 3 323.444 1.624 .197
Within Groups 9160.547 46 199.142
Total 10130.880 49
ESR Between Groups 75.925 3 25.308 1.512 .224
Within Groups 770.075 46 16.741
Total 846.000 49
Leucocyte
Count
Between Groups 1891524.311 3 630508.104 .377 .770
Within Groups 76878275.689 46 1671266.863
Total 78769800.000 49
Between Groups 523.250 3 174.417 1.285 .291
Within Groups 6243.870 46 135.736
Total 6767.120 49
Table:9Anova Other variables Vs prognosis
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Levene's Test
for Equality
of Variances t-test for Equality of Means
F Sig. t Df
Sig. (2-
tailed
Mean
Difference
Std. Error
Difference
95% Confidence
Interval of the
Difference
Lower Upper
ESR Equal
variances
assumed
.046 .830 -1.313 48 .195 -1.75 1.330 -4.420 .928
Equal
variances
not
assumed
-1.250 19.341 .226 -1.75 1.398 -4.668 1.175
Leucocyt
e Count
Equal
variances
assumed
.656 .422 -.702 48 .486 -288.36 410.918
-
1114.564
537.849
Equal
variances
not
assumed
-.779 25.985 .443 -288.36 370.080
-
1049.089
472.374
SGOT Equal
variances
assumed
2.156 .149 -1.556 48 .126 -7.75 4.982 -17.768 2.267
Equal
variances
not
assumed
-1.698 25.011 .102 -7.75 4.566 -17.154 1.653
Cardiac
Enzymes
- CPK –
MB
Equal
variances
assumed
3.021 .089 -2.460 48 .018 -7.77 3.158 -14.116 -1.418
Equal
variances
not
assumed
-2.164 17.230 .045 -7.77 3.589 -15.331 -.204
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Cardiac
Enzymes
- TROP  -
T
Equal
variances
assumed
1.248 .270 -.487 48 .629 -.102 .2093 -.5226 .3189
Equal
variances
not
assumed
-.446 18.269 .661 -.102 .2282 -.5807 .3770
TG Equal
variances
assumed
1.664 .203 -2.074 48 .143 -9.21 4.440 -18.134 -.281
Equal
variances
not
assumed
-2.446 29.939 .121 -9.21 3.764 -16.895 -1.521
LDL Equal
variances
assumed
.525 .472 .032 48 .975 .12 3.633 -7.187 7.420
Equal
variances
not
assumed
.031 19.581 .976 .12 3.788 -7.797 8.030
HDL Equal
variances
assumed
.000 .984 -1.150 48 .256 -2.07 1.805 -5.704 1.554
Equal
variances
not
assumed
-1.159 21.351 .259 -2.07 1.791 -5.795 1.646
Total
Cholester
ol
Equal
variances
assumed
4.731 .035 -2.586 48 .113 -11.35 4.388 -20.170 -2.524
Equal
variances
not
assumed
-3.093 30.981 .104 -11.35 3.669 -18.830 -3.864
Table10 other variables with prognosis  P values
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Other variables, ESR, leucocyte count, SGOT, cardiac enzymes and
lipid profile were corrfelated with prognosis of the ASTEMI patients.All
are not statistically significant except cardiac enzymes CPK-MB.
Picture: 28 - EA A grade Vs Px
A-GRADE
GOOD Px
BAD Px
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Picture: - 29 Percentage of EA B Grade with Good and Bad Px
B-GRADE
GOOD px(89.9%)
BAD Px(10.5%)
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Picture: 30 - Percentage of C GRADE with Good and Bad Px
C-GRADE
GOOD Px(66.6%)
BAD Px(33.3%)
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Figure: 31 - Percentage of D GRADE with Good and Bad Px
D-GRADE
GOOD Px(20%)
BAD Px(80%)
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Frequency % Valid % Cumulative %
Valid ALMI 2 4.0 4.0 4.0
ASMI 2 4.0 4.0 8.0
AWMI 14 28.0 28.0 36.0
EXT 4 8.0 8.0 44.0
HLMI 1 2.0 2.0 46.0
IPW
MI
5 10.0 10.0 56.0
IWMI 20 40.0 40.0 96.0
RVMI 2 4.0 4.0 100.0
Total 50 100.0 100.0
Table: 11 ECG frequency in subjects with ASTEMI
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Picture: 32 - ECG frequency in subjects
Inferior  wall  MI  is  more  frequency  than  other  ASTEMI,  second
common  frequency  is  Anterior  wall  MI,  less  common  frequency   is  RV
MI and High lateral MI.
0
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15
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25
No. of subjects
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COMPLICATIONS:
Frequency % Valid %
Cumulative
%
Valid Nil 37 74.0 74.0 74.0
Died 6 12.0 12.0 86.0
Arrythmia 4 8.0 8.0 94.0
LVF 2 4.0 4.0 98.0
Cardiogenic
Shock
1 2.0 2.0 100.0
Total 50 100.0 100.0
Table: 12- Frequancy of complications in subjects
Out of this fifty patients 37(74%) patients had good prognosis,
4(8%) patients had arrhythmia, 2 patients (4%) had LVF, one patient went
to cardiogenic shock. Six (12%) patients died from ASTEMI.
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DISCUSSION
Acute MIis a major cause of morbidity and mortality
worldwide.Atherosclerosiss i m p l y p u t i s a
chronicinflammationofthevessel wall. Many researchershaveperformed
numerous studiesoverinflammatory markers in a question to
findreliableindicatorfor CHD riskand progression. [16,17,18]In Acute
MI, numerousinflammatorymarkershave been studied and havebeen
linked to poor prognosis.[19-27]
StudiesweredonetoestablishthatEAformationwashigh
inpatientswithCHD.Itis well knownthatthe EAis determined by
forcesactingagainst eachother,repulsionofnegatively charged cells,cell-to-
celladhesionduetoplasmaproteinsandthe force generated byblood
flow.[28-32] EA is increased in various inflammatory
conditionssuchasAMI,acute stroke, sepsis etc. [33,34]and it affects
theoutcomein thepatients.Such chronic
inflammationinthevesselwallmayalsobeassociatedwithinfections andwith
autoimmune diseasesthusindicating the involvement of both humoraland
cell-mediatedimmunemechanismsinCHD. [35-38]
Neumannetaldidastudytodetermine
theprognosticsignificanceofalteredplasmaviscosity andEAin
unstableangina.Itwasastudy of96patientswithunstableangina.
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Thepatientswere
givenstandardizedprotocolmanagementandwereeitherfollowedupforsixmo
nths oruntilsurgicalintervention.Resultsshowedthatplasmaviscosity
andEAwerebetterpredictorfor AMI thanage,gender,fibrinogenlevels,ST
segmentchanges.Also,HoltermonitoringwithSTsegmentanalysisshowedthe
ischemic episodes weremore common in cases with high EA. [39]
         InastudybyRuhenstroth-Bamu,EAvaluewasstudied in groups of
patients  with  and  without  CHD  and  in  normal  subjects  using
theMetricellapparatus.TheresultsshowedthatEAwasstrongly associated
with MI and arteriosclerosis ofperipheralarteries. [40]
ArbeletalperformedastudyshowingEAasacauseofsluggishblood
flow in ACS. [41]In1988,it was recommended by InternationalCommittee
for StandardizationinHematology thatErythrocyte sedimentation
ratecanbe a vitaltestfor the monitoringof chronic inflammatory processes.
[42]Variousstudieswere done andErythrocyte sedimentation
ratewasfoundtohave potential predictiveimportanceinCAD. [19,43]
ErikIngelssonetal found that Erythrocyte sedimentation rate
couldbeastrong predictorofCADmortality.The study was performed
on2,314 middle-agedmenfree fromHF,MI andvalvular heart
disease.Infollow-uptimeof30years,282men developed HF.Thestudy
concluded thatErythrocyte sedimentation ratewasa significantpredictor
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ofHF,independentof other risk factorsfor HF
andAMI.However,inthisstudy,Erythrocyte sedimentation
ratewasdeterminedbyWestergren’s method and Erythrocyte sedimentation
rate greaterthan just 6 mm/hrwas considered to beapositivetest. [44]
Inanotherstudy by Erikssenetal,theErythrocyte sedimentation
ratewasdeterminedin2014healthy menaged40–
60yearsandthetestwasrepeated7yearslater.Erythrocyte sedimentation
ratestrongly correlated withage,haemoglobinlevel,smoking status,total
cholesterollevelandsystolicblood pressure.Erythrocyte sedimentation
ratewas estimated usingWestergren’smethod.ESR>15mm/hr
wasobservedinmenwhohaddevelopedanginaand/or hada positive
stressElectrocardiogram test atthesecondsurvey.Thestudyconcluded by
stating that Erythrocyte sedimentation rateisastrong predictorofCHD
mortality. [45]
AndreaNatalietalalso performedastudy
toevaluatetherelationbetweenErythrocyte sedimentation rateand
theextensionofatherosclerosis(ATS)andCHDmortality.Itwasaretrospective
study withfollowup periodof92months.Study was
performedin1726patientsundergoing angiographyandsubsequentmortality
wererelatedtoErythrocyte sedimentation rateandtootheriskfactors.
Erythrocyte sedimentation ratewasprogressively
higherinthepresenceof1,2,or3-vesseldiseaseandPvalue was<0.0001.In
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thefollow-upperiod,170patientsdiedofacardiaccause.Erythrocyte
sedimentation ratewas consideredhighwhenitwas >18mmand>23
mm/1sthrin malesand
femalesrespectively.ThestudyconcludedthatErythrocyte sedimentation
rateisanindependentcorrelateofcoronaryATSand that itisa predictorofpoor
prognosis inIHD. [46]
InthestudybyAtlaBhagyaLakshmietal,themeanErythrocyte
sedimentation rateofASTEMI(29+17.34) was significantly higher than
the mean Erythrocyte sedimentation rate of control group (15.5
+12.37).PrognosisofthepatientswithASTEMIandcomparisonofgradeswith
Erythrocyte sedimentation rate was not mentioned. [9]
JosephYayanalso performed
astudyonpatientswithanginapectorisandmyocardial
infarctionundergoingaheart catheterexaminationvscontrolgroup.The
Erythrocyte sedimentation rate wasprolongedin79(58.09%)of
136patients.69(50.74%)patientshadCHD with prolongedErythrocyte
sedimentation rate.The Erythrocyte sedimentation
ratewasalsoprolongedinten(7.35%)patientswithoutCHD.
ThespecificityoftheErythrocyte sedimentation
rateforCHDwas70.59%andthesensitivitywas67.65%
whichshowsthatErythrocyte sedimentation rate
isnotalwaysadependablemarker.Thestudy concludedthat Erythrocyte
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sedimentation ratemay beausefuladditionaldiagnosticcriterionforCHD.
[47]Buttheassociation was termedas frequent ratherthan always.
Inviewofvarioussuchstudiesdone,ofalltheparametersavailable,Eryth
rocyte sedimentation ratecame out as a cheap, fast and widely applicable
inflammatorymarker to assess
inflammationandEAinpatientswithCAD.ButErythrocyte sedimentation
ratecorrelates poorly withEAduetotheconfounding effectsof
temperature,PCV, albumin,hemodilutionby anticoagulants.Erythrocyte
sedimentation ratealsodoesnot differentiatewhetherEAcanbe a
causeofcellularfactorsorof plasma factors. [29,33]The Erythrocyte
sedimentation rateisa usefultestinclinicalpracticealsoasanindicator of
otherinflammatoryprocesses,infection,traumaormalignantdisorders,stroke
etc. As
theageofpatientspronetocoronaryarterydiseasesandotherinflammatory
processes likearthritis,vasculitisetc.iscommon;specificity
ofthetestbecomes low.Andthisarise theneed ofatest that correlatesbetterto
assess EA in CHD patients. [9,48]
Hysietalalsodidastudy proposingtheuseofphotoacoustics(PA)forthe
detectionandcharacterizationof RBC aggregationvia 2D simulation.
Sampleswere exposedto1064nmlaserirradiation. Various
concentrationsofDextran-70 were usedtoinduce RBCs
aggregation.Experimentalresultsconfirmedthat PA hadthe abilityto detect
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and quantifyRBCs aggregation. [50]
Berlinerforthefirsttimedidastudy
knownasslidetestontwothousandfive hundredeighty-sixindividuals.They
excludedindividualswithchronicinflammatory diseases, collagenvascular
disease, autoimmune disease or chronic skin disease.
Bloodcount,Erythrocyte sedimentation rateand fibrinogenlevelswere
estimated.Three volumesof venous
bloodwastakenfollowingovernightfastwith1volumeof3.8%sodiumcitrate.
One
dropofthismixturewastrickledontheslideatanangleof30oleavingafinefilm.T
heslidesweredriedroomtemperature,stainedandscannedbyusinganimage
analysis system (INFLAMET). [9,48]
156individualswerefoundto havevasculardisease. There
were95menand61women(M:Fratioas3.1:2)atameanageof61.6+_13.6yrs.
Thestudy wasnot performedonpatientswith a
specificdiagnosisbutstillshowedthat EAmay
beausefulbiomarkershowingsuperiorityoverother commonlyused
markersto detectinflammation in subjects with atherosclerotic heart
disease. [51]
AtlaBhagyaLakshmietal performedastudy withtheaimofusing
aslide testtotestfor EAinsubjectswithacute STEMI,
acuteischemicstrokeand healthycontrols and also to  studythe prognostic
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value of Erythrocyte sedimentation rateandEAATin predictingthe1-
weekoutcomeofthesubjectsofacuteSTEMI andacuteischemic
stroke.TheystudiedthirtysubjectsofacuteSTEMIwhowereadmittedwithin
6hrs of onset of pain in the chest,subjectswith pain lasting more than
30minutes and subjects with1mm
STsegmentelevationinatleasttwocontiguouselectrocardiogram leads. [9]
EAcanbedeterminedaccurately by commercially available
systems,the MyreneRheometerand cell flow meter.
Itanalyzestheaggregatesizedistribution which is expressed
asthenumberofcellsperaggregate,asafunctionofshearstress.However,they
are incredibly expensiveandneeda high-end lab set-up. A
simpleslidetechniqueusing citratedbloodwithimageanalysiswas designed
by Israeli researchers to assess EA.
Zeltseretaldidasimilarstudy wheretheyadaptedasimilar technique
torevealthestateofEAin 206patientswith
ischemicheartdiseaseand134patientswithischemic neurological event. [52]
AtlaBhagyaLakshmietaltooka single largedropof citratedblood(one
volumeof0.8%citratetothreevolumesofblood)andtrickledonaslidepositione
dat 45°.Theslidewasleftinclinedfor10sec.leaving afinefilm. A similar
procedure was followed by us.
Adropofbloodwascollectedbeforecommencingany treatmenttothe patient.
[9]
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The slideswere stainedwithfour to five
dropsofLeishmanstainandleft for two min. This was followedby
twicetheamountof DW.After8min,theslideswere washed, dried and
examined.The subjectswere on follow upfor a weekandtheoutcomes
wererecorded. We deployed asimilar methodology in our
study.Bloodsamplewascollected fromantecubitalveinimmediately
afteradmission.Subsequently,thepatientswere managedaccording
tothestandardtreatmentprotocolofourhospital.Erythrocyte sedimentation
rateby Westergren'smethodandslide
test,EAATwereperformedalongwithother investigations. [9]
Zeltseretaltookthree volumesofvenousbloodwithonevolumeof3.8%
sodiumcitrate.Largedropsofthissamplewereplacedonaslidethatwasheld for
two to three secondsonly
at45°leavingafinefilm.Theslideswerethendriedandautomatic stainingwas
performed bymeans of the HEMA TEK slide stainer. [52]
In thestudybyAtlaBhagyaLakshmi et al,  among thirtypatients
ofAMI,21weremalesand9werefemalesofagerangingfrom26to
80years.Maletofemaleratiowas2.3:1andthemeanageofthesubjects
was51.87± 13.11years.Among
30subjects,therewereseventeenmalesandthirteenfemales. The
sexratiowas1.3:1withmeanage of the controls, 40.966± 12.73
years.Zeltseretalexaminedatotalof134patientswithischemicheartdisease;89
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males and 45 females, M:F ratio 1.99:1. [9]
Inourstudy,outof50patients,38weremalesand12werefemales,M:F
ratio 3.1:1.The age of females ranged from 44-75 years, the average age
being 60.5±10.55years.Theageofmalesrangedfrom28-
77years,theaverageagebeing 55.5±10.5years.Combining
themalesandfemales,the agerangedfrom 26-86years with the
averageagebeing58.1±10.9years.
Inthestudy
byAtlaBhagyaLakshmietal,50%(15of30)ofpatientsofAMI
belongedtoCandDgrades.Amongthecontrols,only2ofthe30subjectsbelonge
d
togradesCandD.Inourstudy,8patientsshowedGradeA,53patientsshowGrad
e B, 34 patients showedGradeC and 5 patients showed GradeDRBC
aggregation. [9]
Inthestudy
byZeltseretalEAwasnotassessedasgrades,rathercomparison wasmade
onthebasisof variablescalledErythrocyte Percentage(EP),Aggregation
Radius(AR)&
VacuumRadius(VR).Asignificant(P<0.0001)correlationwasfound
betweentheEAAandbothfibrinogenconcentrationsandESR.Importantly,the
re wasa subgroupof 49patientswhohadnormalfibrinogenconcentrations
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anda highly significant increment in theEA. [52]
In our study, Outof50patients, 5 showedGradeARBC
aggregationandallofthemhad good prognosis.
Nineteen  19   patients  showed  Grade  B  RBC   aggregation,  out  of
which 17 patients (89.5.6%) had good prognosis, one  patient had
arrhythmia and 1 patients died. Overall therewere2 patients with bad
prognosis (10.5%).
Twenty one (21)showedGrade CRBC aggregation,outof which14
patients (66.7%)  had good prognosis, 7 patients (33.3%) with bad
prognosis.
Five (5)patientsshowedGradeDRBCaggregation.Only
one(20%)hadgood prognosis.2patients(40%)hadarrhythmia and shock
and2patients(40%)died.Overall4 patients (80%) had bad prognosis.
CorrelationofgradesofRBCaggregationwasdone withprognosisofthe
patient and the result was statisticallysignificantwith p value0.006.
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CONCLUSION
EAAT is a non-complex slide test performed in bedside. Theslides
can beassessed subjectivelyandcan
begradedbasedonthedegreeofaggregation. EA isa useful
biomarkertodetectinternalinflammationinindividualswith athero-
thrombotic risk factors.
The  test  mayhave  the  potential  to  assess  the  risk  of  ASTEMI
andalsotoassessprognosisinsubjects withASTEMI.Inthe
presentstudy,greaterEA wasseeninsubjects of ASTEMI
andsignificantcorrelationwas found betweengrades ofEAand prognosis
ofthepatient.  Patients  with  severe  grades  of  EA  C&D  are  high  risk
individuals for complications. The high risk patients are candidates for
PCI (delayed PCI).
Ideallyquantificationofaggregationshould alsoconsider the
thicknessof the aggregate. Specificguidelines are tobe laiddownfor
preparationofslides whichexplain the
amountofbloodtobetaken,amountofanticoagulant tobe
added,concentrationof the anticoagulant,angleof inclinationof slide
andtime span ofinclination.
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Inthe currentstudy,stainedslideswereassessedandgraded. They
werefound tobeexcellentprognostic indicatorsinpatientswith
MI.Itisasimplebedsideprocedure and is less expensive. Thus,it can beused
asascreeningtestforhigh-risk individuals.
Therefore this study concludesthatslide testshowsbetter
correlationwiththe prognosis andaidedwell to detect thepresenceofinternal
inflammation in Acute STEMI.
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SUMMARY
Erythrocyte adhesiveness and aggregation test isa usefulbiomarker
todetectinternal inflammation in individuals with  atherothromboticrisk
factors. Atherosclerosis is
associatedwithchronicinflammationofthearterialwall;therefore,many
researchers have performed various studies overinflammatory markers
and markers of erythrocyteadhesiveness and
aggregationsoastofindreliableindicatorsofcoronary heart
disease(CHD)risk and progression. [16,17,18,63]
EAcanbedeterminedaccurately bycommercially
availablesystems.However,they are very
expensive.ESRisacheap,fastandwidely
applicableinflammatorymarkertoassessinflammationandEA
inpatientswithCHD,butESRcorrelatespoorlywithEA dueto theconfounding
effects. [64]
Sowedidastudy withtheaimofusing thesimpleslidetesttotestfor
EAinsubjectswithacute ST-elevatedMI (ASTEMI)andtostudy
theprognosticvalueofESRandEA and adhesivenesstest(EAAT)inpredicting
the1-weekoutcomeofthese subjects.
Inthe presentstudy,stainedslideswereassessedandgraded.Greater
EAwasseeninsubjectsof acute MIand
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significantcorrelationwasfoundbetweengradesof EAand
prognosisofthepatient.
Patients  with  severe  grades  of  EA  C&D  are  high  risk  individuals
for complications. The high risk individuals are candidates for
percutaneous intervension (delayed PCI) and hence, referred to higher
centre for the same.
Inthepresentstudy,stainedslideswereassessedandgradedandwerefoun
d tobegoodprognostic indicatorsinpatientswith
MI.Itisasimplebedsideprocedure and is cost-effective. Thus,it can beused
asascreeningtestforhigh-risk individuals.
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PROFORMA
I.CASE NO:
II.TITLE:
    Astudy toassessgradesofEAinacuteSTEMI and its prognostic signific-
ance.
III.SUBJECT INFORMATION:
Name:
Age:
Sex:
Address:
Occupation:
IV.PRESENT HISTORY:
COMPLAINTS:
? Pain in the cental or lateral chest wall (feeling oftightness or heavi-
ness,pressure, orsqueezing)
? Pain radiating to lowerjaw, neck, left arm, back, orepigastric region
? Breathlessness or dyspnoe)
? Excessivesweating
? Palpitations
? Nausea,Vomiting
? LOC(loss of consciousness)
V.PAST HISTORY
? Any past historyofmedication
? DM/SHT
? Previous history heart Surgeries
? Hypercholestrolemiaor familial disorder
VI.PERSONAL HISTORY
135
? Diet:Vegetarian/ Non vegetarian
? Bladder and bowel habits:Regular/Irregular
? Addiction- chronic tobacco use, ethanol consumption, history of
Smoking, drug abuse
VII.GENERAL EXAMINATION
? Built
? Nourishment
? Cyanosis
? Pallor
? Jaundice
? Pedal edema
? Lymphadenopathy
VIII.VITALS
1. Pulse: per min
Rate, Rhythm, Character, Volume, Condition of the vessel wall,
radio femoral delay
2. Blood pressure: mm/Hg
3. Temperature:  °F
4. Respiratory Rate:
VIII.SYSTEM EXAMINATION
1. Cardiovascularsystem examination:
2. Respiratorysystem examination:
3. Abdomen:
4. Central nervous system examination:
IX. INVESTIGATIONS
136
1. EA AND ADHESIVENESS TEST
2. ECG:
3. COMPLETE BLOOD COUNT-TC,DC,HB
4. ERYTHROCYTE SEDIMENTAION RATE
5. RFT WITH ELECTROLYTES
6. LFT-ENZYMES,SGOT
7. LIPID PROFILE-TG,LDL,HDL,TOTAL CHOLESTEROL
8. CARDIAC ENZYMES – CPK, LDH
9. ECHO
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Bµõ´a]°ß ÂÁµ®:
Bµõ´a] ø©¯®: Aµ_ RÌ£õUP® ©¸zxÁU PÀ¿¶ ©¸zxÁ©øÚ
÷{õ¯õÎ°ß ö£¯º:
 ÷{õ¯õÎ°ßÁ¯x:
£vÄGs:
1 ÷©ØSÔ¨¤mkÒÍBµõ´a]°ß ÷{õUPzøu²® £¯øÚ²®
¬ÊÁx©õP ¦¶¢xöPõs÷hß. ÷©¾® GÚxAøÚzx
\¢÷uP[PøÍ²® ÷PmkAuØPõÚÂÍUP[PøÍ²®
öuÎÄ£kzvUöPõs÷hß.
2 ÷©¾® C¢uBµõ´a]USGÚx ö\õ¢u Â¸¨£zvß ÷£¶À
£[÷PØQ÷ÓßGßÖ®, ÷©¾® G¢u ÷{µzv¾® GÆÂu
¬ßÚÔÂ¨¦ªßÔC¢uBµõ´a]°¼¸¢x Â»P
¬Êø©¯õÚE¶ø© EÒÍøu²®, CuØSGÆÂu \mh
¤øn¨¦® CÀø» Gß£øu²® AÔ÷Áß.
3 Bµõ´a]¯õÍ÷µõ, Bµõ´a] EuÂ¯õÍ÷µõ, Bµõ´a] E£¯zuõ÷µõ,
Bµõ´a] ÷£µõ]¶¯÷µõ, KÊ[Sö{Ô ö\¯ØSÊ EÖ¨¤ÚºP÷Íõ
G¨÷£õx ÷Ásk©õÚõ¾® GÚxAÝ©v°ßÔGÚx
EÒ÷{õ¯õÎ £vÄPøÍC¢uBµõ´a]UPõP÷ÁõAÀ»xGvºPõ»
¤Ó Bµõ´a]PÐUPõP÷Áõ £¯ß£kzvUöPõÒÍ»õ® GßÖ®
÷©¾® C¢u |£¢uøÚ {õßCÆÁµõ´a]°¼¸¢x Â»QÚõ¾®
uS® GßÖ® J¨¦UöPõÒQ÷Óß. B°Ý® GÚxAøh¯õÍ®
\®£¢u¨£mhG¢u £vÄPÐ® (\mh§ºÁ©õÚ ÷uøÁPÒuÂµ)
öÁÎ°h¨£h©õmhxGßÓEÖvö©õÈ°ß ö£¯¶À
C¢uBµõ´a]°¼¸¢x QøhUP¨ö£Ö® ¬iÄPøÍöÁÎ°h
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©Ö¨¦ öuÔÂUP©õm÷hßGßÖEÖv¯ÎUQß÷Óß.
4 C¢uBµõ´a]US {õß ¬Ê©Úxhß \®©vUQß÷ÓßGßÖ®
÷©¾® Bµõ´a]U SÊÂÚº GÚUS AÎUS®
AÔÄøµPøÍuÁÓõx ¤ß£ØÖ÷ÁßGßÖ®
EÖv¯ÎUQß÷Óß.
5 C¢uBµõ´a]USz ÷uøÁ¨£k® AøÚzx ©¸zxÁ¨
£¶÷\õuøÚPÐUS® JzxøÇ¨¦
u¸÷ÁßGßÖEÖv¯ÎUQß÷Óß.
6 C¢uBµõ´a]US ¯õ¸øh¯ ÁØ¦Özu¾ªßÔ GÚx ö\õ¢u
Â¸¨£zvß ÷£¶¾® _¯AÔÄhÝ® ¬Ê©ÚxhÝ®
\®©zvUQß÷ÓßGßÖCuß - »®
J¨¦UöPõÒQ÷Óß.
÷{õ¯õÎ°ßøPö¯õ¨£® / ö£¸ÂµÀ øP÷µøP
Ch®:      ÷uv:
Bµõ´a]¯õÍ¶ßøPö¯õ¨£®
Ch®:      ÷uv:
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MASTER CHART
Case
No. Name Age Sex ECG
Erythro-
cyte ag-
gregation
grade
ESR
mm/
hr
LEUCO-
CYTE
COUNT
Cells/cum
m
ECHO
SGOT
IU/L
Cardiac En-
zymes
LIPID PROFILE
Progno-
sis with-
in 1
Week
period
Complications
TG
mg%
LD
L
mg
%
HD
L
mg
%
TOTAL
CHOLE-
STEROL
mg%
CPK-
MB
IU/L
TRO
P-T
ng/L
1. Ramdev 65 M AW-
MI
     B 30    12100 RWMA
AW
75 63 6.0 156 105 48 184 GOOD NIL
2. Srinivasan 76 M IWMI B 32    11600 RWMA
IW
48 55 6.9 137 90 50 213 GOOD NIL
3. Nagavalli 60 F IWMI      B 26    10300 RWMA
IW
60 73 5.7 158 94 36 206 GOOD NIL
4. Rajeshwari 50 F IWMI D 30    11200 RWMA IW 72 80 7.1 166 86 42 190 BAD DIED
5. Kuppan 51 M ASMI C 24    10800 RWMA IVS 40 59 6.5 175 84 38 208 GOOD NIL
6. Raja 35 M IWMI C 20    9600 RWMA IW 65 79 7.0 159 110 41 200 BAD ARRYTHMIA
7. Ramesh 28 M IWMI A 22    11000 RWMA IW 55 67 6.3 142 120 40 190 GOOD NIL
8. Subramani 60 M RVM
I
B 26    11500 RWMA
IW+P
35 51 5.4 168 115 32 208 GOOD NIL
9. Madhan 45 M ALMI C 20    10400 RWMA AW 40 55 5.9 172 95 45 220 GOOD NIL
10. Saravanan 45 M AW-
MI
A 28    12200 RWMA AW 45 60 7.3 160 98 37 189 GOOD NIL
11. Kowsalya 75 F AW-
MI
B 30    13000 RWMA AW 54 70 6.2 175 89 43 225 GOOD NIL
12. Baskar 45 M IPW
MI
B 26    10300 RWMA IW+P 70 81 6.3 166 85 50 230 GOOD NIL
13. Moideenkhan 56 M IWMI C 25    9800 RWMA IW 62 50 6.8 109 118 42 180 GOOD NIL
14. Venkat 53 M IWMI A 28 9700 RWMA IW 72 52 6.0 173 95 37 210 GOOD NIL
15. Sekar 58 M IPW
MI
B 30 8600 RWMA IW+P 85 48 7.3 153 99 39 189 GOOD NIL
16. Edward 32 M EXT
AW-
C 20 11000 RWMA  AW 64 58 6.5 148 115 33 186 GOOD NIL
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Case
No. Name Age Sex ECG
Erythro-
cyte ag-
gregation
grade
ESR
mm/
hr
LEUCO-
CYTE
COUNT
Cells/cum
m
ECHO
SGOT
IU/L
Cardiac En-
zymes
LIPID PROFILE
Progno-
sis with-
in 1
Week
period
Complications
TG
mg%
LD
L
mg
%
HD
L
mg
%
TOTAL
CHOLE-
STEROL
mg%
CPK-
MB
IU/L
TRO
P-T
ng/L
MI
17. Chinnathai 64 F AW-
MI
D 32 9400 RWMA AW 58 62 5.5 168 86 47 205 BAD DIED
18. Ramesh 38 M IWMI C 18 12200 RWMA IW 45 66 6.7 156 100 50 176 GOOD NIL
19. Sumathi 65 F IWMI C 28 11500 RWMA IW 60 53 6.2 175 105 40 212 BAD DIED
20. Bakyaraj 57 M IWMI       B 24 7900 RWMA IW 75 69 5.3 167 112 36 209 GOOD NIL
21. Mamtha 75 F IPW
MI
C 28 9200 RWMA IW+P 95 65 5.9 162 92 34 216 BAD DIED
22. Ravi 46 M IWMI C 22 8900 RWMA IW 80 72 7.0 153 96 38 198 GOOD NIL
23. Mangalaksmi 77 F AW-
MI
      B 24 10200 RWMA AW 70 50 6.6 150 85 30 188 GOOD NIL
24. Thiruvengadam 57 M IWMI C 28 11300 RWMA IW 48 57 5.7 148 117 44 192 GOOD NIL
25. Lakshmi 61 F AW-
MI
C 30 10700 RWMA AW 68 49 6.4 166 110 46 202 BAD ARRYTHMIA
26. Rajamuthu 41 M AW-
MI
A 20 11800 RWMA AW 52 71 6.9 154 106 31 190 GOOD NIL
27. Velayutham 47 M EXT
AW-
MI
C 24 12000 RWMAAW 85 76 5.3 164 112 48 212 BAD DIED
28. Muthu 50 M IWMI B 20 9600 RWMA IW 78 56 6.9 159 106 35 209 GOOD NIL
29. Louis 59 M ALMI A 20 11200 RWMA AW 55 63 7.3 149 98 39 185 GOOD NIL
30. Murugan 52 M IWMI B 28 10400 RWMA IW 60 71 5.9 132 92 40 179 GOOD NIL
31. Ibrahim 50 M AW-
MI
D 23 12200 RWMA IW 64 85 6.0 172 106 47 220 BAD LVF
32. Vijayan 44 M IPW
MI
B 19 9000 RWMA IW+P 90 81 5.7 154 86 36 201 GOOD NIL
33. Anthonyamma 70 F AW-
MI
C 30 10500 RWMA AW 52 63 7.0 169 120 40 216 GOOD NIL
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Case
No. Name Age Sex ECG
Erythro-
cyte ag-
gregation
grade
ESR
mm/
hr
LEUCO-
CYTE
COUNT
Cells/cum
m
ECHO
SGOT
IU/L
Cardiac En-
zymes
LIPID PROFILE
Progno-
sis with-
in 1
Week
period
Complications
TG
mg%
LD
L
mg
%
HD
L
mg
%
TOTAL
CHOLE-
STEROL
mg%
CPK-
MB
IU/L
TRO
P-T
ng/L
34. Sivakumar 63 M EXT
AW-
MI
D 32 11200 RWMA AW 65 58 5.5 170 82 33 207 BAD ARRYTHMIA
35. Laksmi 50 F AW-
MI
B 25 9000 RWMA AW 48 67 6.3 163 87 49 193 GOOD NIL
36. Venkatesan 30 M EXT
AW
C 18 9600 RWAM AW 52 77 7.4 173 94 50 208 BAD ARRYTHMIA
37. Basha 38 M IWMI B 20 8600 RWMA IW 80 69 6.7 165 108 42 220 GOOD NIL
38. Palani 60 M IWMI C 30 10200 RWMA IW 45 56 5.4 157 93 46 180 GOOD NIL
39. Ganesan 52 M AW-
MI
B 20 13200 RWMA AW 88 49 6.4 175 99 35 225 GOOD NIL
40. Egambaram 55 M AW-
MI
C 27 11400 RWMA AW 40 58 5.8 140 106 38 190 GOOD NIL
41. Subramani 39 M IWMI B 20 9800 RWMA IW 40 54 5.2 120 86 38 197 GOOD NIL
42. Fathima 44 F IWMI B 22 11000 RWMA IW 76 61 6.3 146 110 45 192 GOOD NIL
43. Salim 55 M IWMI C 27 10400 RWMA IW 45 62 7.1 153 90 38 212 BAD CARDIOGENIC-
SHOCK
44. Syed 45 M RVM
I
C 28 12500 RWMA IW+P 82 71 6.6 160 100 40 206 GOOD NIL
45. Harinath 49 M AW-
MI
B 25 11600 RWMA AW 70 82 7.3 136 120 48 217 BAD LVF
46. Syedbasha 62 M HLMI B 30 12000 NO
RWMA
80 73 6.7 170 96 40 230 BAD DIED
47. Kanniyappan 58 M ASMI C 28 11500 RWMA SEPT 56 67 6.1 145 88 44 182 GOOD NIL
48. Emmanuel 50 M AW-
MI
C 26 8800 RWMA AW 65 48 5.8 165 92 38 197 GOOD NIL
49. Ayusha 65 F IPW
MI
C 30 9200 RWMA IW+P 35 51 7.4 151 96 50 186 GOOD NIL
50. Mohan 60 M IWMI D 27 9000 RWMA IW 50 65 5.5 163 88 46 204 GOOD NIL
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